Pfizer is planning to sweeten its bid for British rival AstraZeneca for a second time, people with knowledge of the matter said.
Pfizer and its advisers are crafting a new offer that would increase the value modestly above the current 50 pounds-a-share (about $84) level while bumping the cash portion, said two of the people, who asked not to be identified discussing private information. Pfizer will probably wait until after British government hearings to raise...
Subscribe from just €1 for the first month!
All Digital Access + eReader
Unlimited Access for 1 Month
Then €19.99 a month after the offer period.
€149 For the 1st Year
Unlimited Access for 1 Year
90 Day Pass
Unlimited Access for 2 Years
Get a Business Account for you and your team